TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38906614
Drug: Insulin-and-pramlintide closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-and-pramlintide closed-loop system with simple meal announcements
Study: 38906614
Drug: Insulin-and-placebo system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-and-placebo system with carbohydrate counting
Study: 38907052
Drug: Narrow-diameter tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-diameter tissue level implant in T2DM patients
Study: 38907052
Drug: Narrow-diameter tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-diameter tissue level implant in normoglycemic patients
Study: 38907104
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg every 4 weeks (starting dose 160 mg)
Study: 38907106
Drug: Phenylephrine (PE)
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine (PE) infusion at 15-20 mikrg/min adjusted until preload was restored (SVV < 12%)
Study: 38907679
Drug: rhPro-UK 35
Normalized name: Vital E- Repro
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPro-UK 35 mg (15 mg bolus + 20 mg infusion/30 min)
Study: 38907679
Drug: rt-PA 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA 0.9 mg/kg (10% bolus + 90% infusion/1 h)
Study: 38907679
Drug: rhPro-UK 35
Normalized name: Vital E- Repro
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPro-UK 35 mg
Study: 38907935
Drug: Insulin efsitora
Normalized name: Insulin efsitora alfa
DrugBank: Insulin efsitora alfa (DB19013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin efsitora alfa (efsitora)
Study: 38907935
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (glargine)
Study: 38908841
Drug: ePRO intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ePRO intervention (responsive web application for weekly symptom reporting with proactive follow-up by nurses for 6 weeks)
Study: 38909093
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy alongside usual care
Study: 38909144
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg/day for approximately 80% of patients, 15 mg/day for the remaining patients)
Study: 38909189
Drug: Tartarase dentifrice
Normalized name: tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartarase dentifrice (used twice daily)
Study: 38909189
Drug: Tartarase dentifrice
Normalized name: tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartarase dentifrice (used with dental tray for 30 min, then brushed again once daily)
Study: 38909671
Drug: Baseline follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline follicle-stimulating hormone levels
Study: 38909740
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 25 mg weekly oral
Study: 38909740
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.5 g twice daily oral
Study: 38909877
Drug: Tafamidis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis treatment
Study: 38909998
Drug: ChitoCare gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChitoCare gel
Study: 38910002
Drug: Vaginal application
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal application of Vagifem 30 µg once a day for 14 days prior to colposcopy
Study: 38910002
Drug: Vaginal application
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal application of Vagifem 30 µg
Study: 38911348
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg nicotine cigarettes
Study: 38911584
Drug: steroid/anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroid/anesthetic
Study: 38911647
Drug: Cancer treatment
Normalized name: Retinoids for cancer treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer treatment in past 6 months
Study: 38912296
Drug: Ustekinumab (UST)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab (UST) therapy
Study: 38912654
Drug: Tirzepatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (10 mg or 15 mg)
Study: 38912692
Drug: Tailored aggressive
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored aggressive hydration (TAH) - 20 mL/kg bolus post-ERCP and 3 mL/kg/hr during and after ERCP
Study: 38912692
Drug: Tailored standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored standard hydration (TSH) - 1.5 mL/kg/hr lactated Ringer's solution during and after ERCP
Study: 38912884
Drug: 5% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% human albumin solution (HAS)
Study: 38912905
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with high triglyceride to total cholesterol (TG/TC) ratio
Study: 38913539
Drug: Lanreotide autogel/depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel/depot (120 mg every 28 days) plus best supportive care (BSC)
Study: 38913574
Drug: Remdesivir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remdesivir (200 mg on day 1; 100 mg daily up to day 5)
Study: 38913710
Drug: VRC07-523LS IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS IV 2.5 mg/kg
Study: 38913710
Drug: VRC07-523LS IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS IV 5 mg/kg
Study: 38913710
Drug: VRC07-523LS IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS IV 20 mg/kg
Study: 38913710
Drug: VRC07-523LS SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS SC 2.5 mg/kg
Study: 38913710
Drug: VRC07-523LS SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS SC 5 mg/kg
Study: 38913710
Drug: VRC07-523LS IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS IM 2.5 mg/kg
Study: 38913881
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab plus chemotherapy (n=762)
Study: 38913881
Drug: Neoadjuvant placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant placebo plus chemotherapy (n=383)
Study: 38914016
Drug: 177 Lu-DOTATATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT)
Study: 38914085
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (continue or terminate the thrombectomy procedure)
Study: 38914270
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rivaroxaban twice daily plus 100 mg aspirin daily
Study: 38914270
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rivaroxaban twice daily
Study: 38914294
Drug: PDS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS with ranibizumab 100 mg/ml with fixed refill-exchanges every 24 weeks (Q24W)
Study: 38914294
Drug: Supplemental intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental intravitreal ranibizumab injections
Study: 38914481
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound (HIFU) treatment with a 30% increase in intensity
Study: 38914694
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g ENSO 16
Study: 38914876
Drug: Trazo/Gaba 2.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazo/Gaba 2.5/25 mg t.i.d. for 8 weeks
Study: 38914876
Drug: Trazo/Gaba 5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazo/Gaba 5/50 mg t.i.d. for 8 weeks
Study: 38914876
Drug: Trazo/Gaba 10/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazo/Gaba 10/100 mg t.i.d. for 8 weeks
Study: 38914976
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride 10% spray (experimental group)
Study: 38915038
Drug: Lever Positioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lever Positioning Manipulation (LPM) treatment, administered once every two days for a total of 12 times over 4 weeks.
Study: 38915038
Drug: Sham LPM
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham LPM treatment, administered during the same period as Group 1.
Study: 38915038
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (Group 3) without LPM treatment.
Study: 38915065
Drug: TNFi (tumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi (tumor necrosis factor inhibitor)
Study: 38915106
Drug: Opioid taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid taper support program with PA intervention at weeks 1, 2, 4, 8, 12, 16, and 20 after discharge.
Study: 38915117
Drug: DynaFiT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DynaFiT therapy (bortezomib, lenalidomide, dexamethasone; daratumumab for frail patients)
Study: 38915117
Drug: DynaFiT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DynaFiT therapy
Study: 38915115
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg PO every other day
Study: 38915115
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg PO twice daily
Study: 38915115
Drug: Traditional blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional blood glucose lowering therapy + ramipril 10 mg PO
Study: 38915423
Drug: Omigapil at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omigapil at daily doses ranging from 0.02 to 0.08 mg/kg for 12 weeks after a 4-week vehicle run-in.
Study: 38915796
Drug: CTLA4-Ig and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA4-Ig and interleukin-2 (IL-2) therapy
Study: 38915873
Drug: Perinatal antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perinatal antibiotics usage
Study: 38916221
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - received oral/written information about the anaesthetic-surgical process and remained in a playroom waiting for surgery.
Study: 38916223
Drug: Methylnaltrexone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone (0.15 mg/kg/d for 5 days)
Study: 38916429
Drug: DNA-HIV-PT123 vaccine
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-HIV-PT123 vaccine with AS01B adjuvant
Study: 38916429
Drug: DNA-HIV-PT123 vaccine
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-HIV-PT123 vaccine with MF59 adjuvant
Study: 38916429
Drug: Low-dose protein/adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose protein/adjuvant with AS01B
Study: 38916429
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of DNA with AS01B-adjuvanted bivalent Env gp120
Study: 38916717
Drug: Vericiguat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat (10 mg target dose)
Study: 38916892
Drug: Subcutaneous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous buprenorphine
Study: 38917111
Drug: Video directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video directly observed therapy (VDOT) for hydroxyurea
Study: 38917404
Drug: Outpatient high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient high-dose methotrexate (HD-MTX) with glucarpidase 2000u
Study: 38917525
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily plus mesalamine 1 g three times daily for 6 months
Study: 38917525
Drug: Mesalamine 1
Normalized name: mesalamine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 1 g three times daily for 6 months
Study: 38918103
Drug: Ad26.COV2.S booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S booster (other dose levels)
Study: 38918590
Drug: Topical simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical simvastatin
Study: 38918590
Drug: Topical atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical atorvastatin
Study: 38918780
Drug: TB/TBI treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB/TBI treatment
Study: 38918869
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) techniques with 12 weeks of direct acting antiviral (DAA) treatment
Study: 38919522
Drug: TP-based induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP-based induction chemotherapy followed by radiotherapy (IC+RT)
Study: 38919522
Drug: cisplatin-based concurrent
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin-based concurrent radiochemotherapy (CRT)
Study: 38919826
Drug: Spartalizumab (PDR001)
Normalized name: Natalizumab
DrugBank: Spartalizumab (DB14892)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Spartalizumab (PDR001) 300 mg intravenous every three weeks until disease progression or unacceptable toxicity
Study: 38920407
Drug: Adavosertib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (300 mg QDAY by mouth on days 1-5 and 8-12 of each 21-day cycle)
Study: 38922435
Drug: Telerehabilitation home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telerehabilitation home program (TRP) in addition to pharmaceutical treatment
Study: 38922435
Drug: Pharmaceutical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical treatment (Control)
Study: 38922520
Drug: DKP/TRAM 25/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKP/TRAM 25/75 mg every 8 h (n=211)
Study: 38922689
Drug: Twice Weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice Weekly Hemodialysis
Study: 38922689
Drug: Thrice Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice Weekly Hemodialysis
Study: 38922906
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day DHA supplementation during pregnancy (PGO-800)
Study: 38922906
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day DHA supplementation during pregnancy (PGO-200)
Study: 38922990
Drug: On demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On demand (OD) treatment with rFIXFc, n=22
Study: 38923140
Drug: Evidence-based guideline-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based guideline-directed medical therapy (GDMT)
Study: 38923140
Drug: Comorbidity treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comorbidity treatment
Study: 38923140
Drug: Sequence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence of treatment introduction and up-titration
Study: 38923439
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin prophylaxis from <16 weeks until 36 weeks for high-risk women
Study: 38923439
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin prophylaxis for high-risk women
Study: 38923871
Drug: ABBV-599 high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg QD)
Study: 38923871
Drug: Upadacitinib and
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib and ABBV-599 high dose
Study: 38923910
Drug: Tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus chemotherapy (TIS+Chemo)
Study: 38923965
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine administered twice daily with optical defocus (DIMS lenses)
Study: 38923965
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine administered twice daily (single vision lenses)
Study: 38924429
Drug: AZD3152 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3152 (600 mg intramuscular injection)
Study: 38924429
Drug: AZD3152 (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3152 (prophylactic administration)
Study: 38924724
Drug: Atogepant 30
Normalized name: atogepant 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 30 mg BID
Study: 38924724
Drug: Atogepant 60
Normalized name: atogepant 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 60 mg QD
Study: 38924732
Drug: Benralizumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (30 mg subcutaneous every 4 weeks)
Study: 38924779
Drug: Normal after-visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal after-visit summary (treatment as usual)
Study: 38924855
Drug: Induction systemic
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction systemic therapy followed by complete local treatment
Study: 38925354
Drug: BEP supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEP supplementation (two 75-g sachets per day)
Study: 38925354
Drug: BEP supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEP supplementation + Azithromycin (20 mg/kg at 42 days)
Study: 38925586
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PEG-rhG-CSF
Study: 38925586
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg PEG-rhG-CSF
Study: 38925586
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PEG-rhG-CSF (BW ≤ 60 kg)
Study: 38925586
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg PEG-rhG-CSF (BW ≤ 60 kg)
Study: 38925586
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PEG-rhG-CSF (BW > 60 kg)
Study: 38925586
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg PEG-rhG-CSF (BW > 60 kg)
Study: 38925694
Drug: umbilical cord-derived
Normalized name: Allogenic umbilical cord-derived mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: umbilical cord-derived mesenchymal stem cells (UC-MSCs) treatment
Study: 38925712
Drug: Ultrasound-guided PENG
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided PENG block with 18 mL of 0.5% ropivacaine mixed with 2 mL of a contrast agent
Study: 38925803
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice daily on days 1-3, followed by 0.5 mg daily thereafter)
Study: 38925869
Drug: High-dose allogeneic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose allogeneic disc progenitor cells
Study: 38925869
Drug: Low-dose cells
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cells
Study: 38926068
Drug: 27.476 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27.476 IU YF vaccine
Study: 38926068
Drug: 10.447 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.447 IU YF vaccine
Study: 38926068
Drug: 3.013 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.013 IU YF vaccine
Study: 38926068
Drug: 587 IU
Normalized name: choline salicylate 587 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 587 IU YF vaccine
Study: 38926068
Drug: 158 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 158 IU YF vaccine
Study: 38926068
Drug: 31 IU
Normalized name: GLYCERETH-31
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31 IU YF vaccine
Study: 38926142
Drug: exergame and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: exergame and acceptance and commitment therapy (e-ACT) programme
Study: 38926142
Drug: acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: acceptance and commitment therapy (ACT) only
Study: 38926266
Drug: Mavacamten 15
Normalized name: mavacamten 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten 15 mg plus activated charcoal 50 g administered 2 h after mavacamten dosing
Study: 38926266
Drug: Mavacamten 15
Normalized name: mavacamten 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten 15 mg plus activated charcoal 50 g administered 6 h after mavacamten dosing
Study: 38926266
Drug: Mavacamten 15
Normalized name: mavacamten 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten 15 mg alone
Study: 38926732
Drug: Ustekinumab (UST)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab (UST) treatment
Study: 38931260
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of DMB (150 mg DMB/tablet)
Study: 38931260
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of DMB (300 mg DMB/tablet)
Study: 38931260
Drug: Placebo (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (300 mg freeze-dried strawberry)
Study: 38931864
Drug: eOD-GT8 60mer
Approvals — FDA: no, EMA: no, PMDA: no
Description: eOD-GT8 60mer vaccine candidate
Study: 38931864
Drug: Purified products
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified products from 1 L scale
Study: 38934093
Drug: Baseline or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline or after one treatment cycle
Study: 38934147
Drug: Ritlecitinib 200/50-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 200/50-mg
Study: 38934147
Drug: Ritlecitinib 10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 10-mg